"Patient-reported outcomes during pelvic radiation therapy: A secondary" by Kelsey L. Corrigan, Rebecca Paulus et al.
 

Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203

Kelsey L. Corrigan, University of Texas MD Anderson Cancer Center, Houston, TX.
Rebecca Paulus, NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
Ann H. Klopp, University of Texas MD Anderson Cancer Center, Houston, TX.
Lari B. Wenzel, University of California-Irvine, Irvine, CA.
Anamaria R. Yeung, University of Florida, Gainesville, FL.
J Spencer Thompson, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Desiree E. Doncals, Summa Health System, Akron, OH.
Vijayananda Kundapur, Saskatoon Cancer Centre, Saskatoon, SK, Canada.
Nancy H. Wiggers, Northside Radiation Oncology, Alpharetta, GA, accruals under Georgia NCORP.
Dasarahally S. Mohan, Kaiser Permanente, San Francisco, CA.
Sharad A. Ghamande, Augusta University Georgia Cancer Center, Augusta, GA.
Shannon N. Westin, University of Texas MD Anderson Cancer Center, Houston, TX.
Kara L. Schnarr, McMaster University and Juravinski Cancer Centre, Hamilton, ON, Canada.
Michael L. Haas, Reading Hospital, West Reading, PA.
David K. Gaffney, University of Utah/Huntsman Cancer Institute, Salt Lake City, UT.
Steven E. Waggoner, Case Western Reserve University and Cleveland Clinic, Cleveland, OH.
Pamela J. Vanderwall, Advocate Health - MidwestFollow
Noha T. Jastaniyah, King Faisal Specialist Hospital, Riyadh, Saudi Arabia, accruals under UCSF.
Stephanie L. Pugh, NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
Lisa A. Kachnic, Columbia University, Herbert Irving Comprehensive Cancer Center, Minority-underserved NCORP, New York, NY.

Affiliations

Aurora BayCare Medical Center

Abstract

Purpose:NRG-RTOG 1203 reported that intensity-modulated radiation therapy (IMRT) reduced patient-reported GI toxicities in patients with cervical/endometrial cancer receiving postoperative RT, compared with 3-dimensional conformal radiation therapy (3DRT). We conducted a secondary analysis of patient-reported sexual function (PR-SF) among treatment groups to identify factors associated with sexual dysfunction.

Methods and materials:Patients on NRG-RTOG 1203 were randomly assigned to 3DRT versus IMRT and completed Patient-Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) and FACT-Cx surveys at baseline, week 5 of RT, and at 4-6 weeks, 1 year, and 3 years after RT. Patient responses to FACT-Cx sexual function questions were analyzed. The between-arm frequency and severity of responses and their comparison with PRO-CTCAE GI toxicity were tested using chi-square tests. A repeated-measures logistic regression model was used to determine the impact of clinical and treatment factors on PR-SF.

Results:Two hundred thirty-six patients completed PR-SF questions; 125 (53%) received 3DRT and 111 (47%) IMRT. There were no significant differences in PR-SF between groups ( P > .05). After RT, responses to "I am afraid to have sex" and "I am interested in sex" significantly improved over time ( P = .007 and P = .03, respectively). At 1 year after RT, women with interference from abdominal pain were more bothered by odor from the vagina versus women with no interference of abdominal pain (5% v 0%, P = .006). Additionally, at 1 year after RT, women with no severity of abdominal pain or no interference from abdominal pain liked their body appearance more versus women with at least some abdominal pain or some interference from abdominal pain (34% v 13%, P = .003 and 32% v 6%, P = .001, respectively).

Conclusion:PR-SF was similar between treatment groups. After RT, fear of sex declined and interest in sex improved over time. Women with GI toxicity after RT completion are at risk for worse sexual function.

Document Type

Article

PubMed ID

40370492

Teammate Access


 

Share

COinS